| Name | Title | Contact Details |
|---|---|---|
Milan Shah |
Chief Technology Officer | Profile |
Jaydev Thakkar |
Chief Operating Officer | Profile |
We are a global biotechnology company, specializing in discovering, developing, and delivering innovative therapies for the treatment of neurodegenerative, non-malignant hematologic and autoimmune diseases to patients worldwide. As a company, we are focused on cutting-edge science and medicines that address unmet patient needs and change the course of these devastating diseases. Founded in 1978, we are the world`s oldest independent biotechnology company and take pride in being known for pioneering the development of leading multiple sclerosis therapies. With approximately 7,000 employees worldwide, we are focused on better understanding the underlying biology of diseases so we can discover and deliver innovative treatments that make a real difference in the lives of patients. We also put great focus on being good corporate citizens. Our commitment to corporate citizenship extends to patient education and support programs, giving back to the communities in which we operate, promoting and advancing science education, and operating in a sustainable manner. These cultural imperatives are directly incorporated into our business activities.
HotSpot Therapeutics is discovering new allosteric therapies with the ability to treat disease in new ways.
GangaGen Inc is a Palo Alto, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Agenus is an immuno-oncology company driven by innovation and speed. Our goal is to treat cancers with novel combinations utilizing our unique portfolio of checkpoint antibodies, tumor microenvironment modifiers, vaccines and adjuvants. In addition to a broad portfolio, we have an accomplished team of scientists, novel technology platforms and fully-integrated end-to-end capabilities from discovery to GMP manufacturing. With our remarkable combination of science and people, we believe that we are uniquely positioned to bring curative treatments to cancer patients.
Iterion Pharmaceuticals is a venture-backed, clinical stage biotechnology company developing novel targeted cancer therapeutics.